[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373505":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":40,"collaborators":7,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":7,"maxAge":52,"enrollmentInfo":7,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"University of Miami","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Diiodothyropropionic acid (DITPA)","Drug Administration",[14],{"name":15,"affiliation":5,"role":16},"Roy E Weiss, M.D.","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","(305) 243-1944","rweiss@med.miami.edu",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"University of Miami, Miller School of Medicine","AVAILABLE","Miami","Florida","33136","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-80.19366,25.77427,{"lat":35,"lon":34},[38,39],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},{"name":15,"role":16,"phone":7,"phoneExt":7,"email":7},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Roy E. Weiss, M.D.","Principal Investigator","100373505","rescue-of-infants-with-mct8-deficiency-100373505",false,"NCT04143295","Rescue of Infants With MCT8 Deficiency","DITPA","Inclusion Criteria\n\n* Genetic Confirmation: Male fetus or fetuses (including monozygotic twin pregnancies) must have a confirmed MCT8 gene mutation.\n* Family History: A previously born child or children with a severe, typical phenotype and an MCT8 gene mutation identical to that of the fetus.\n* Alternatively, the mother or a sister must have a relative with a known MCT8 defect.\n* Parental Decision: Parental refusal to terminate the pregnancy despite the diagnosis of MCT8 deficiency.\n* Compliance and Availability: Willingness of the parents to comply with all study procedures and ensure availability for the duration of the study.\n\nExclusion Criteria:\n\n• Pregnancy-Related Factors: Dizygotic (non-identical) twin pregnancy (unless only one fetus is confirmed with the MCT8 mutation, and the unaffected fetus will not be treated).\n\nParental decision to terminate the pregnancy.\n\n• Maternal Medical Conditions: Hyperthyroidism requiring treatment. Significant liver or kidney insufficiency. Congestive heart failure. Hyperemesis gravidarum unresponsive to treatment.\n\n* Significant cardiac conditions, including:\n* Atrial fibrillation or other arrhythmias.\n* Unstable angina.\n* Coronary heart disease.\n* Medications:\n\nCurrent use of sympathomimetic therapy. Anticoagulant therapy. Use of Cytochrome P450 2C9 (CYP2C9) inhibitors with a narrow therapeutic index.\n\n• Other Factors: Major illness or recent major surgery within four weeks of baseline visit 1, unrelated to MCT8 deficiency.","MALE","18 Years","EXPANDED_ACCESS","Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.",[56],"Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency","2025-12-03",{"date":59,"type":60},"2025-12-11","ACTUAL",{"name":42,"class":6},1]